| Old Articles: <Older 8441-8450 Newer> |
|---|
 |
BusinessWeek
July 25, 2005
Gene G. Marcial |
Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion.   |
BusinessWeek
July 25, 2005
Gene G. Marcial |
Spectrum's Cancer Drugs Could be Winners Biotechs got battered earlier this year, but some investors are optimistic about Spectrum Pharmaceuticals because of the anticancer agents it has in advanced clinical trials. |
The Motley Fool
July 15, 2005
W.D. Crotty |
National City's Knockout Numbers The financial company's second-quarter results far exceed analysts' estimates. |
The Motley Fool
July 15, 2005
Tim Beyers |
Stunning News for Taser The stun-gun maker is exonerated in a California court. Could more good times lie ahead? Investors, read on. |
The Motley Fool
July 15, 2005
Andrew Patterson |
RedEnvelope, Red Shareholders RedEnvelope announced some good news! It's restating earnings! Unless management shows that it has better control of all elements of the business, this company is doomed to remain "perpetually undervalued." |
The Motley Fool
July 15, 2005
Tom Taulli |
China vs. Congress: What's Next? Bulging with dollars, China needs to do something with the money. Why not buy U.S. companies? The deal that is getting much of the attention is CNOOC's pursuit of Unocal, which is the ninth-largest U.S. oil company. Congress is very concerned. |
The Motley Fool
July 15, 2005
Nick Baker |
Fool by Numbers: GE Q2 2005 General Electric released second quarter results: Income Statement Highlights... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
July 15, 2005
Seth Jayson |
Shocker for Your Short List Meet the company the author can't wait to short: Law Enforcement Associates. A move to the American Stock Exchange may finally put one of Taser's pretenders into short territory. |
The Motley Fool
July 15, 2005
Stephen D. Simpson |
A Pick and Shovel Play Bucyrus is a less well-known play on the renewed demand for mining equipment. It's hard to say what to do with these shares. |
The Motley Fool
July 15, 2005
Stephen D. Simpson |
Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit. |
| <Older 8441-8450 Newer> Return to current articles. |
